Search

Displaying results 4061 - 4070 of 7059 in total
  1. Drug

    Setileuton

    go.drugbank.com/drugs/DB19550
    Investigational

    Setileuton has a monoisotopic molecular weight of 463.12 Da. … Setileuton is a small molecule drug. The usage of the INN stem '-leuton' in the name indicates that Setileuton is a 5-lipo-oxygenase inhibitor, anti-inflammatory.

  2. Drug

    Ledaborbactam etzadroxil

    go.drugbank.com/drugs/DB21455
    Investigational

    Ledaborbactam etzadroxil has a monoisotopic molecular weight of 391.18 Da. … Ledaborbactam etzadroxil is a small molecule drug. The usage of the INN stem '-bactam' in the name indicates that Ledaborbactam etzadroxil is a ẞ-lactamase inhibitor.

  3. Drug

    Azetukalner

    go.drugbank.com/drugs/DB21551
    Investigational

    Azetukalner has a monoisotopic molecular weight of 368.23 Da. … Azetukalner is a small molecule drug. The usage of the INN stem '-kalner' in the name indicates that Azetukalner is a opener of calcium-activated (maxi-K) K+-channel.

  4. Drug

    Icovamenib

    go.drugbank.com/drugs/DB21669
    Investigational

    Icovamenib has a monoisotopic molecular weight of 566.28 Da. … Icovamenib is a small molecule drug. The usage of the INN stem '-menib' in the name indicates that Icovamenib is a menin interaction inhibitor.

  5. Drug

    Riboprine

    go.drugbank.com/drugs/DB11933
    Investigational

    Ipa has been used in trials studying the treatment of Nausea and Surgical Site Infection.

    Mixtures: CitraNatal 90 DHA
  6. Drug

    Pralatrexate

    go.drugbank.com/drugs/DB06813
    ApprovedInvestigational

    [A246693] Pralatrexate is designed to have a higher affinity for the reduced folate carrier, a protein that is overexpressed in malignant cells and is upregulated by oncogenes. … [A246703] Pralatrexate was approved by the FDA on September 24, 2009.

  7. Drug

    Elacestrant

    go.drugbank.com/drugs/DB06374
    ApprovedInvestigational

    [L44918,L44948] It received a similar approval in the EU in September 2023. … Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist.

  8. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer.

  9. Drug

    Somapacitan

    go.drugbank.com/drugs/DB15093
    ApprovedInvestigational

    [A219146] Somapacitan was granted FDA approval on 28 August 2020.[L15666] … Somapacitan, also known as NNC0195-0092,[A219136] is a growth hormone analog indicated to treat adults with growth hormone deficiency.

  10. Drug

    Zanidatamab

    go.drugbank.com/drugs/DB15471
    ApprovedInvestigational

    Zanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2). … [A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903]